Key Takeaway: Travere Therapeutics is set to announce its financial results for the fourth quarter and full year of 2025. The report will include details on inducement grants made under Nasdaq listing rule 5635(c)(4). This announcement reflects the company's commitment to transparency and compliance with regulatory standards.
Price reaction · baseline $30.055 (2026-02-12T16:29:00.000Z) · hit during market hours · clean, no other TVTX news in the window
day 0 close · peak
+1.8%
Market Sentiment Analysis
POSITIVE FACTORS
Travere Therapeutics is preparing to report its financial results.
The company is adhering to Nasdaq listing requirements.
Inducement grants indicate potential growth and investment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
4.7%
average across 9 past catalysts
Lead asset
sparsentan
Phase 3 · Immunoglobulin A Nephropathy
Full Press Release Details
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results View Full Press Release Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Frequently Asked Questions
When will Travere Therapeutics report its financial results?
Travere Therapeutics is set to report its financial results for Q4 and FY 2025.
What does the Nasdaq listing rule 5635(c)(4) entail?
This rule involves disclosure requirements related to inducement grants.
What are inducement grants?
Inducement grants are incentives offered to attract and retain talent.